Swiss National Bank’s Ligand Pharmaceuticals LGND Stock Holding History

Swiss National Bank’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Buy	39,000 +100	+0.3%	+$23.6K	0.01%	914
2026 Q1	$7.77M	Buy	38,900 +300	+0.8%	+$59.4K	﹤0.01%	1099
2025 Q4	$7.3M	Buy	38,600 +1,200	+3%	+$231K	﹤0.01%	1146
2025 Q3	$6.63M	Buy	37,400 +600	+2%	+$89.2K	﹤0.01%	1181
2025 Q2	$4.18M	Buy	36,800 +200	+0.5%	+$21.4K	﹤0.01%	1386
2025 Q1	$3.85M	Buy	36,600 +600	+2%	+$67.9K	﹤0.01%	1414
2024 Q4	$3.86M	Buy	36,000 +900	+3%	+$102K	﹤0.01%	1484
2024 Q3	$3.51M	Buy	35,100 +2,000	+6%	+$201K	﹤0.01%	1526
2024 Q2	$2.79M	Buy	33,100 +400	+1%	+$31.8K	﹤0.01%	1631
2024 Q1	$2.39M	Buy	32,700 +200	+0.6%	+$14.7K	﹤0.01%	1742
2023 Q4	$2.32M	Sell	32,500 -3,600	-10%	-$212K	﹤0.01%	1749
2023 Q3	$2.16M	Buy	36,100 +800	+2%	+$52.7K	﹤0.01%	1792
2023 Q2	$2.55M	Sell	35,300 -1,200	-3%	-$90K	﹤0.01%	1733
2023 Q1	$2.68M	Sell	36,500 -4,200	-10%	-$299K	﹤0.01%	1645
2022 Q4	$2.72M	Sell	40,700 -23,420	-37%	-$1.52M	﹤0.01%	1697
2022 Q3	$3.44M	Buy	64,120 +801	+1%	+$47.1K	﹤0.01%	1506
2022 Q2	$3.52M	Hold	63,319	–	–	﹤0.01%	1537
2022 Q1	$4.44M	Buy	63,319 +4,489	+8%	+$326K	﹤0.01%	1517
2021 Q4	$5.67M	Sell	58,830 -160	-0.3%	-$14.8K	﹤0.01%	1375
2021 Q3	$5.13M	Buy	58,990 +320	+0.5%	+$24.8K	﹤0.01%	1443
2021 Q2	$4.8M	Sell	58,670 -320	-0.5%	-$26.6K	﹤0.01%	1522
2021 Q1	$5.61M	Buy	58,990 +641	+1%	+$60.6K	﹤0.01%	1384
2020 Q4	$3.62M	Hold	58,349	–	–	﹤0.01%	1558
2020 Q3	$3.47M	Sell	58,349 -641	-1%	-$43.7K	﹤0.01%	1414
2020 Q2	$4.12M	Buy	58,990 +4,328	+8%	+$274K	﹤0.01%	1255
2020 Q1	$2.48M	Sell	54,662 -3,687	-6%	-$209K	﹤0.01%	1321
2019 Q4	$3.8M	Sell	58,349 -481	-0.8%	-$32.1K	﹤0.01%	1331
2019 Q3	$3.65M	Sell	58,830 -2,084	-3%	-$131K	﹤0.01%	1285
2019 Q2	$4.34M	Sell	60,914 -1,282	-2%	-$94.4K	﹤0.01%	1212
2019 Q1	$4.88M	Buy	62,196 +2,564	+4%	+$194K	0.01%	1094
2018 Q4	$5.05M	Hold	59,632	–	–	0.01%	977
2018 Q3	$10.2M	Buy	59,632 +802	+1%	+$121K	0.01%	731
2018 Q2	$7.6M	Hold	58,830	–	–	0.01%	841
2018 Q1	$6.06M	Buy	58,830 +481	+0.8%	+$47.6K	0.01%	937
2017 Q4	$4.98M	Buy	58,349 +2,404	+4%	+$208K	0.01%	1065
2017 Q3	$4.75M	Hold	55,945	–	–	0.01%	1049
2017 Q2	$4.24M	Buy	55,945 +3,687	+7%	+$258K	0.01%	1097
2017 Q1	$3.45M	Buy	52,258 +962	+2%	+$63.3K	﹤0.01%	1229
2016 Q4	$3.25M	Hold	51,296	–	–	0.01%	1241
2016 Q3	$3.27M	Sell	51,296 -160	-0.3%	-$11.7K	0.01%	1183
2016 Q2	$3.83M	Buy	51,456 +3,847	+8%	+$285K	0.01%	1057
2016 Q1	$3.07M	Buy	47,609 +10,099	+27%	+$614K	0.01%	1162
2015 Q4	$2.54M	Hold	37,510	–	–	0.01%	1171
2015 Q3	$2M	Buy	37,510 +4,969	+15%	+$301K	0.01%	1306
2015 Q2	$2.05M	Buy	32,541 +2,565	+9%	+$140K	0.01%	1294
2015 Q1	$1.44M	Hold	29,976	–	–	﹤0.01%	1522
2014 Q4	$995K	Hold	29,976	–	–	﹤0.01%	1734
2014 Q3	$879K	Hold	29,976	–	–	﹤0.01%	1738
2014 Q2	$1.17M	Sell	29,976 -2,725	-8%	-$111K	﹤0.01%	1626
2014 Q1	$1.37M	Buy	32,701 +7,534	+30%	+$314K	0.01%	1491
2013 Q4	$826K	Sell	25,167 -3,847	-13%	-$125K	﹤0.01%	1658
2013 Q3	$783K	Sell	29,014 -1,443	-5%	-$40.6K	﹤0.01%	1622
2013 Q2	$711K	Buy	+30,457	New	+$548K	﹤0.01%	1673

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss National Bank's LGND Position: Q2 2026 in Review

Swiss National Bank increased its Ligand Pharmaceuticals (LGND) stake by 0.26% in Q2 2026, buying an estimated $23.6K and bringing the position to 39,000 shares worth $12.3M. The position accounts for 0.01% of the portfolio, ranked #914.

Swiss National Bank first reported a position in LGND in Q2 2013 and has held it in 53 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Swiss National Bank held 39,000 shares of Ligand Pharmaceuticals worth $12.3M as of Q2 2026.
Swiss National Bank bought 100 Ligand Pharmaceuticals shares in Q2 2026, an estimated $23.6K.
Ligand Pharmaceuticals made up 0.01% of Swiss National Bank's portfolio in Q2 2026, its #914 holding.
Swiss National Bank first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.